We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The city of Boston has become the latest municipality encouraging the importation of prescription drugs to receive a warning from the FDA about the dangers such programs create for consumers.
Fears that changing the formula for calculating reimbursements for Rx drugs through Medicare will significantly reduce the volume of cancer drugs prescribed for patients are probably exaggerated, according to a drug industry analyst.
Two FDA advisory committees will meet jointly Sept. 13-14 to consider the agency’s analysis of the findings of a group of experts that examined study data on the effects of several antidepressants on patients.
A new study released this week indicates that the Medicare-approved drug discount cards provide significant savings compared to retail prices paid by cash customers.
An interagency task force established in January is developing a set of enforcement procedures that will provide various agencies with uniform and effective strategies to halt illicit drug importation.
Bayer Biological Products (Bayer BP) is employing innovative antitampering strategies as part of the company’s ongoing effort to combat product tampering and counterfeiting.
The Senate Finance Committee is demanding an investigation into drug companies responsible for overcharging federal health programs for pharmaceuticals; the committee is also hinting that it may be time to get tougher with delinquents.
The Centers for Medicare & Medicaid Services (CMS) released a proposed rule yesterday that would dramatically affect the amount Medicare pays for prescription drugs — in some cases lowering the cost to the government by as much as 89 percent.
Proposed regulations implementing the prescription drug savings available through the Medicare discount drug card were announced by HHS Secretary Tommy Thompson yesterday.
A pharmaceutical industry task force has recommended that the use of radio-frequency tags for identifying and tracking drug products at the individual item level be at the heart of a system to secure product integrity throughout the supply chain.